

---

**From:** Masha Drokova <[REDACTED]>  
**Sent:** Friday, November 3, 2017 3:13 AM  
**To:** Steven Sinofsky  
**Cc:** jeffrey E.  
**Subject:** Re:

Thank you for the comprehensive feedback Steven.

For me the main value is that the system is an order-of magnitude cheaper than existing technologies, premised on leveraging data to help users see what daily elements are affecting their blood sugar, and predicting dangerous highs and lows before they happen so they can take actions beforehand. To date, their beta app has lowered blood sugar averages in over 5% of users 2x better than the world's most prescribed diabetes drug, Metformin. Which means that with the help of the data diabetes would need to use less drugs. However I'd agree on complexity of regulations and saturation on the market.

I run Day One Ventures fund and based in San Francisco. I'd be happy to connect in person sometime to learn about your experience and tell about our investments and opportunities I see.

On Nov 2, 2017, at 3:24 PM, Steven Sinofsky <[REDACTED]> wrote:  
<[REDACTED]>

Greetings Masha,  
<[REDACTED]>

I apologize for the delay. I was at some events in the UK where I did not have connectivity.

I have worked on a related portfolio company so I will have to be a bit abstract on the specifics of this opportunity. So please excuse these brief thoughts. Also, the only information I had was what was provided in your mail which was limited relative to any detailed analysis.

\* In general the challenge with glucose measurement is the finger prick. Any device that relies on this will only be marginally better than any other device, whether or not there is software or a slightly more convenient measuring device. This is a statement about the inconvenience of a prick (and long term challenges) but also the medical challenges on relying on that point in time.</div>

\* My sense is that going down the path of an innovation, that still has a prick, but requires a level of FDA approval is a difficult one to approach.

\* This is a very crowded space. There are a lot of apps, a lot of measuring devices, a lot of mixtures of app and measuring devices. It is very difficult to avoid appearing as a commodity to consumers.

\* While I understand there is potential to see innovation using novel approaches to analysis of data, it is not clear to me how much better the approach can be for an individual with data.

\* The real opportunity I might see is around measuring glucose or some related telemetry to assist in compliance that is outside the scope of a finger prick and measuring glucose directly. It seems like we should have some other data point upon which to apply machine learning.

I hope this helps...any friend of JE is a friend of mine.

On Nov 1, 2017, at 4:43 PM, Masha=Drokov [REDACTED] wrote:

Th=nk you Jeffrey. Steve, great meeting you.  
Would appreciate y=ur feedback

On Nov 1, 2017, at 9:31 AM, jeffrey E. <=a href="mailto:jeevacation@gmail.com">jeevacation@gmail.com> wrote=

steve can you=give some guidance

On Wed, Nov 1, 2017 at 12:20 PM, Masha Drokov [REDACTED] <mailto:n [REDACTED]> wrote:

<https://drive.google.com/file/d/0B5O93D3IJArEbXBsdII4elVob0U/=wbr>view>

<=pan>Center Health is building a= AI-based glucose monitoring system for the 1 in 11 Americans who suff=r from diabetes, based on machine learning and their personalized AI, =ria. Users subscribe to their disposable test strips, a \$148/yr US market, w=ich are delivered monthly, as Aria learns about their diabetes and prompts b=havioral changes to lower blood sugar. The system is an order of m=gnitude cheaper than existing technologies, premised on leveraging data to h=lp users see what daily elements are affecting their blood sugar, and p=redicting dangerous highs and lows before they happen. </=iv>

Pros

— Existing glucometers from big companies=are very old-fashioned and outdated, those companies make their revenue fro= overpriced strips  
— Direct competitors, such as =/span>iHealth and Dario have negative customer reviews and minor  
—&=bsp;Uses FDA-approved circuits to get the approval in an automated manner</=ont>

=i>Cons

— Enormous pr=ssure both from the industry players and companies such as Apple and Google=that try to develop non-invasive glucose monitoring that will wipe out test=strip products  
<=ont face="Roboto-Regular">— Hardware startup without a product to=sell yet, finalizing the development  
— Young team =

--

please not=

The information contained in this communication is confidential= may be attorney-client privileged, may constitute inside information, a=d is intended only for the use of the addressee. It is the property ofJEE Unauthorized use, disclosure or copying of this communication or=any part thereof is strictly prohibited and may be unlawful. If you have=received this communication in error, please notify us immediately by jeevacation@gmail.com <mailto:jeevacation@gmail.com> , and destroy this communication a=d all copies thereof, including all attachments. copyright -all rights r=served

=